Exploring the Role of Patient Preferences in Hepatocellular Carcinoma Treatment Decisions: A Qualitative Study

Hepatocellular carcinoma (HCC) treatment decisions are often complex and may become increasingly so as new treatment options emerge.Improved understanding of tradeoffs and patient preferences in treatment decisions will enhance patient-provider discussions, facilitate patient-centered trials to develop new treatments, and inform HCC treatment guidelines.This qualitative study of patients and providers provided information on the values considered in HCC treatment decisions and the importance of considering the tradeoffs of efficacy, toxicity, and inconvenience/costs.These insights can be used to develop preference elicitation tools, perform large-scale preference elicitation surveys, and systematically assess and incorporate patient preferences into treatment decisions.

Authors

Institutions

Publication Details

Journal
MDM Policy & Practice
Published
2025-01-01
DOI
https://doi.org/10.1177/23814683251340055
Primary Topic
Hepatocellular Carcinoma Treatment and Prognosis
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Exploring the Role of Patient Preferences in Hepatocellular Carcinoma Treatment Decisions: A Qualitative Study

Andrew M. Moon, Tammy Triglianos, Michael D. Kappelman, David Mauro et al.
MDM Policy & Practice
Hepatocellular Carcinoma Treatment and Prognosis
article

Exploring the Role of Patient Preferences in Hepatocellular Carcinoma Treatment Decisions: A Qualitative Study

Andrew M. Moon, Tammy Triglianos, Michael D. Kappelman, David Mauro, Jonathan Phillips, Ted K. Yanagihara, Randall Teal, Jessica Carda-Auten, Donna M. Evon, A. Sidney Barritt, Daniel R. Richardson, Ashwin Somasundaram, David A. Gerber, Neil Shah, Myra Waheed, Lynne I. Wagner, Hanna K. Sanoff, Oren K. Fix, Jonathan D Sorah, Hersh Shroff, Gabriel V. Lupu, Ethan Basch, Jingquan Jia, Matthew Schooler, Hiwot A. Ekuban, Ariel E. Sanderford
article en

Abstract

Hepatocellular carcinoma (HCC) treatment decisions are often complex and may become increasingly so as new treatment options emerge.Improved understanding of tradeoffs and patient preferences in treatment decisions will enhance patient-provider discussions, facilitate patient-centered trials to develop new treatments, and inform HCC treatment guidelines.This qualitative study of patients and providers provided information on the values considered in HCC treatment decisions and the importance of considering the tradeoffs of efficacy, toxicity, and inconvenience/costs.These insights can be used to develop preference elicitation tools, perform large-scale preference elicitation surveys, and systematically assess and incorporate patient preferences into treatment decisions.

MDM Policy & PracticeVol. 10(1)
University of North Carolina at Chapel Hill (US), UNC Lineberger Comprehensive Cancer Center, University of Cincinnati (US)
American Association for the Study of Liver Diseases
Good health and well-being
Openalex Percentile: Top 82%
Hepatocellular Carcinoma Treatment and Prognosis
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.